R. Desai

发表

Molecular classification of human cancers using a 92-gene real-time quantitative polymerase chain reaction assay.

R. Salunga, Xiao-Jun Ma, M. Erlander, 2009, Archives of pathology & laboratory medicine.

Interrogation of transcriptomic changes associated with drug-induced hepatic sinusoidal dilatation in colorectal cancer

P. Hegde, J. Martens, J. Vogt, 2018, PloS one.

Correction: Next Generation MUT-MAP, a High-Sensitivity High-Throughput Microfluidics Chip-Based Mutation Analysis Panel

Rajesh Patel, R. Desai, R. Raja, 2014, PLoS ONE.

Next Generation MUT-MAP, a High-Sensitivity High-Throughput Microfluidics Chip-Based Mutation Analysis Panel

Rajesh Patel, R. Desai, R. Raja, 2014, PloS one.

Efficacy, Safety, and Pharmacodynamic Effects of the Bruton’s Tyrosine Kinase Inhibitor Fenebrutinib (GDC‐0853) in Systemic Lupus Erythematosus: Results of a Phase II, Randomized, Double‐Blind, Placebo‐Controlled Trial

J. Galanter, D. Isenberg, L. Chinn, 2021, Arthritis & rheumatology.

Phase I study of the anti-α5β1 monoclonal antibody MINT1526A with or without bevacizumab in patients with advanced solid tumors

P. Hegde, K. Wong, L. Rosen, 2018, Cancer Chemotherapy and Pharmacology.

Biomarkers and associations with the clinical activity of PD-L1 blockade in a MPDL3280A study.

J. Sosman, F. Hodi, S. Gettinger, 2013 .

Abstract B153: A phase I study evaluating the pharmacokinetics (PK) and pharmacodynamic (PD) activity of the dual PI3K/mTOR inhibitor GDC-0980 administered once weekly (QW).

G. Jayson, J. Ware, J. Soria, 2011 .

Mutation Scanning Using MUT-MAP, a High-Throughput, Microfluidic Chip-Based, Multi-Analyte Panel

Rajesh Patel, R. Desai, R. Raja, 2012, PloS one.

A Novel Method for Mutation Analysis Using Genomic DNA Obtained from Immunohistochemistry-Stained Sections

L. Amler, H. Koeppen, I. McCaffery, 2015 .

Biomarker Analyses from a Placebo-Controlled Phase II Study Evaluating Erlotinib ± Onartuzumab in Advanced Non–Small Cell Lung Cancer: MET Expression Levels Are Predictive of Patient Benefit

I. Wistuba, J. Zha, L. Rangell, 2014, Clinical Cancer Research.

VERONICA: Randomized Phase II Study of Fulvestrant and Venetoclax in ER-Positive Metastatic Breast Cancer Post-CDK4/6 Inhibitors – Efficacy, Safety, and Biomarker Results

T. Wilson, A. Bardia, T. Decker, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

An Antibody–Drug Conjugate Directed against Lymphocyte Antigen 6 Complex, Locus E (LY6E) Provides Robust Tumor Killing in a Wide Range of Solid Tumor Malignancies

Karen E Gascoigne, P. Haverty, S. Spencer, 2015, Clinical Cancer Research.

Anti-EGFL7 antibodies enhance stress-induced endothelial cell death and anti-VEGF efficacy.

P. Hegde, I. Kasman, A. Jubb, 2013, The Journal of clinical investigation.

Development of a robust RNA-based classifier to accurately determine ER, PR, and HER2 status in breast cancer clinical samples

G. Hampton, J. Fridlyand, T. Wilson, 2014, Breast Cancer Research and Treatment.

Exploratory biomarker analyses from OAM4558g: A placebo-controlled phase II study of erlotinib with or without MetMAb in patients with advanced non-small cell lung cancer (NSCLC).

L. Amler, R. Yauch, A. Pandita, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Results from VERONICA: A randomized, phase II study of second-/third-line venetoclax (VEN) + fulvestrant (F) versus F alone in estrogen receptor (ER)-positive, HER2-negative, locally advanced, or metastatic breast cancer (LA/MBC).

A. Bardia, T. Decker, G. Bertelli, 2021, Journal of Clinical Oncology.

An antibody drug conjugate (ADC) directed against Lymphocyte Antigen 6 Complex, Locus E (LY6E) provides robust tumor killing in a wide range of solid tumor malignancies Running Title: Preclinical development of a LY6E antibody drug conjugate

Karen E Gascoigne, P. Haverty, S. Spencer, 2015 .

Targeted Biomarker Profiling of Matched Primary and Metastatic Estrogen Receptor Positive Breast Cancers

G. Hampton, T. Wilson, J. Spoerke, 2014, PloS one.

PAK1 mediates pancreatic cancer cell migration and resistance to MET inhibition

R. Neve, D. Aust, C. Pilarsky, 2014, Journal of Pathology.